


July 29-31, 2024 | Boston, MA
gamma-delta-t-therapies.com

BOOK BY MAY 10
& SAVE \$850



5th Annual

Gamma Delta T Therapies Summit

Driving Clinical Response Through Antibody & Cell-Based $\gamma\delta$ T

**Uncover the Biological Nuances of
Gamma Delta T Cells to Inform your
Translational Strategy including
Targeting Specificity, Combination
Strategies & Product Development
to Confidently Progress to Clinic**

Expert Speakers Include:



Francesco Galimi
Chief Medical Officer
Adicet Bio



Lawrence Lamb
Executive Vice
President & Chief
Scientific Officer
IN8Bio



Charlie Morris
Chief Medical Officer
LAVA Therapeutics



Nelli Bejanyan
Associate Professor
**Moffit Cancer
Center**



Stefanos Theoharis
Chief Executive Officer
**OneChain
Immunotherapeutics**



Antara Banerjee
Senior Director, Head
Immune Cell Engager
Therapies
Takeda

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.gamma-delta-t-therapies.com



WELCOME


EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 5th Annual Gamma Delta T Therapies Summit



5th Annual
Gamma Delta T
Therapies Summit

July 29-31, 2024 | Boston, MA

The landscape of gamma delta T cells is steadily evolving and advancing towards clinical applications. With a consistent flow of progress in the clinic seen recently by **Adicet Bio**, **Kiromic**, **TC Biopharma** and further progression preclinically from **CytoMed**, **Acepodia**; the field is beginning to see the potential of the gamma delta therapies validated across oncology and autoimmune disorders.

Returning for the fifth year, the annual **Gamma Delta T Therapies Summit** is aligning forces with industry experts from **Takeda**, **OneChain Immunotherapeutics**, **LAVA Therapeutics** and more, in a masterclass showcasing of the novel practices on **vd1** and **vd2 subsets** from R&D through to the clinic and beyond. Covering innovative approaches to unlock clinical benefits by **expanding current biological depth** in knowledge, fine tuning key mechanisms and **epigenetic engineering strategies**, **streamlining clinical trial designs** through clear inclusion and exclusion criteria, **balancing safety and efficacy**, **optimizing manufacturing practices for enhanced functionality**, and deciphering the intricate **interactions of gamma delta T Cells within the TME**.

As the **ONLY industry focused, gamma delta T cell meeting taking place in 2024**, this is your chance to “part the sea” of challenges standing in the way of clinical progress. With **two dedicated tracks** specifically designed to cover all major challenges across “**Research and Translational Development**” and “**Clinical Development and Product Optimization**”, designed to help progress your gamma delta T cell pipelines into the clinic, with:

- Clinical case studies** outlining safety and efficacy data, and regulatory feedback on IND submissions
- Combination approaches** to better target the gamma delta biology and stimulate a stronger immune response
- Sequencing analysis** to identify TCR specificity and optimal tumor targets
- Manufacturing considerations for IND submissions** to achieve consistent quality of product development

This meeting serves as a perfect melting pot for large pharma, biotech and academia to combine high quality research with clinical focus. It is pivotal to join with your community in 2024 to understand their clinical safety and efficacy to further cement confidence that this approach could be a game-changer for the cell therapy and antibody space.

KEY BENEFITS OF ATTENDING



Explore the biological nuances of gamma delta T cells exploring both engineered and non-engineered cell therapies. Deep dive into past and current clinical data, deciphering the intricate complexities of the TME and overcoming challenges in manufacturing. Led by industry and academic experts including— **IN8Bio**, **Adicet Bio**, **University College London**, and many more!



Fine tune your mechanisms of gamma delta T cells for precise solid and liquid tumor targeting. Covering essential techniques including antibody-cell conjugation, gamma delta-TIL, combinatory approaches with checkpoint inhibitors, and gene engineering strategies to enhance the efficacy and specificity of your gamma delta T therapy. Led by **Kiromic**, **Acepodia**, **University of Pittsburgh Cancer Center!**



Participate in **15+ clinical case studies from large pharma, biotech and academia** alike, addressing end-to-end challenges from preclinical testing to challenges within the clinic to helping you create a robust clinical road map for your gamma delta T therapy - with **LAVA Therapeutics**, **Moffitt Cancer Center**, **Luminary Therapeutics**.



Improve the translational success of your gamma delta T cell therapies from preclinical models to clinical applications. Bridging the gap between experimental efficacy and clinical outcomes requires a deep understanding of the factors influencing translatability and who better to learn from than **Takeda**, **Unicet Biotech**, **OneChain Immunotherapeutics**.



Take inspiration from the **role of gamma delta T cells in autoimmune diseases** as **Luminary Therapeutics**, **Adicet Bio** and **Unicet Biotech** walk through the learnings across exploration of preclinical evidence, safety considerations, potential adverse effects, personalized treatment approaches and current clinical data for autoimmune diseases to inform your own translational strategies.

What our speakers have to say:

“The scientific content of this meeting far exceeded those in the past and brought together a near-perfect combination of industry updates and the state of translational research and clinical trials”

Chief Scientific Officer,
IN8Bio

“The meeting was a great opportunity to learn from leaders in the field, both from academia and industry. Also, a great forum to network. The organization was impeccable”

Scientist, **J&J Innovative Medicine**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Expert Speakers

5th Annual
**Gamma Delta T
Therapies Summit**
July 29-31, 2024 | **Boston, MA**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Sai-wen Tang
Director, Research & Development
Acepodia Biotech



Francesco Galimi
Chief Medical Officer
Adicet Bio



Ekatherina Goryachi
Head of Clinical Operations
Adicet Bio



Jyothi Sethamaranu
Director, MSAT
Adicet Bio



Frank Borriello
Chief Executive Officer
Alloplex Biotherapeutics



Jose Conejo-Garcia
Chief Scientific Officer
Cellepux Therapeutics



Payam Zarin
Associate Director
GentiBio



Mohammed Alnaggar
Associate Professor
Hubei University of Technology



Christopher Holland
Senior Manager, Research
Immunocore



Lawrence Lamb
Executive Vice President & Chief Scientific Officer
IN8Bio



Trishna Goswami
Chief Medical Officer
IN8Bio



Alan Guerrero
Vice President - Research & Development Cell Therapy
Kiromic



Charlie Morris
Chief Medical Officer
LAVA Therapeutics



Jeff Liter
President & Chief Executive Officer
Luminary Therapeutics



Beau Webber
Chief Science Officer & Founder
Luminary Therapeutics



Nelli Bejanyan
Associate Professor
Moffit Cancer Center



Meisam Naeimi
Kararoudi, Professor
Nationwide Children's Hospital



Laura Garcia Perez
Senior Scientist
OneChain Immunotherapeutics

Your Expert Speakers



Stefanos Theoharis
Chief Executive Officer
OneChain
Immunotherapeutics



Ed Zhang
CEO
Overland
Pharmaceuticals



Haiyan Jiang
Founder & Chief Scientific
Officer
PointLoma Biosciences



Xiaohong Wang
Director
PointLoma Biosciences



Nandhu Sobhana
Head of Cell Therapy
Innovation IND Engine
Takeda



Antara Banerjee
Senior Director, Head
Immune Cell Engager
Therapies
Takeda



Bryan Kobel
Chief Executive Officer
TC Biopharma



David Taggart
Product Development
Supervisor
TC Biopharm



Weiwei Ma
Chief Technology Officer
Unicet Biotech



Cathriona Foley
Assistant Professor
University College Cork



Jonathan Fisher
Principal Investigator
University College
London



Marta Barisa
Senior Manager - Scientific
Project & Research Fellow
University College
London




Michael Lotze
Professor of Surgery,
Immunology &
Bioengineering
University of Pittsburgh

“ I really enjoyed talking with top investigators in
the field and to learn from their experience. ”

Principal Scientist, **Immatics**

Agenda At a Glance



5th Annual
Gamma Delta T
Therapies Summit

July 29-31, 2024 | Boston, MA

Bootcamp Day: Advanced Understanding of Gamma Delta T Cell Biology | Monday, July 29

Exploring the Evolving Landscape of Gamma Delta Cells to Improve Future Clinical Trial Designs

Delving into the Mechanisms and Pathways Underpinning Gamma Delta T Cell Cytotoxicity

Tuesday, July 30

Plenary Presentations

Morning Break & Speed Networking

Research & Translational Development

Clinical Development & Product Optimization

Fine-Tuning Mechanisms of Gamma Delta T Cells for Precise Solid Tumor Targeting

Streamlining Clinical Trial Design for Improved Targeting of the TME

Lunch Break

Exploration of Engineering Strategies and their Influence on Cellular Attributes

Model Techniques in Developing $\gamma\delta$ T Cells at a Commercial Scale

Afternoon Break & Poster Session

Plenary Presentations

Conference Day 2 | Wednesday, July 31

Plenary Presentations

Morning Break & Networking

Research & Translational Development

Clinical Development & Product Optimization

Contrasting Approaches in Gamma Delta T Cell Engagers and Cell Therapies

Optimization of Manufacturing to Aid Functionality Whilst Preserving Innate Killing

Lunch Break

The Role of Gamma Delta T Cells in Autoimmune Diseases

Enhancing Functionality of Gamma Delta T Cells Whilst Preserving Innate Killing

Afternoon Break

Plenary Presentations

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Bootcamp Day: Advanced Understanding of Gamma Delta T Cell Biology

Monday, July 29

The basic biology bootcamp will navigate through the intricacies of gamma delta T cell functions, exploring both engineered and non-engineered cell therapies cells including antibodies, and combination therapies. From fundamentals to advanced concepts, this immersive and comprehensive program is designed to provide participants with an in-depth understanding of the basic biology of gamma delta T cells. Join us for a day of exploration and learning which will influence your future therapeutic designs and clinical strategy.

Exploring the Evolving Landscape of Gamma Delta Cells to Improve Future Clinical Trial Designs

9:00 Clinical Review Session: Unveiling the Enigma: Exploring Past & Present Clinical Insights into Gamma Delta Cells

An extensive break down of past and present clinical trials that have mapped the field of gamma delta T cells. From here we are able to identify definitive reasoning behind successes and failures and how this will predict what the future of gamma delta T therapies will look like.

- Delve into historical milestones and breakthroughs that have shaped our understanding of gamma delta cells in clinical contexts
- Explore recent advancements and emerging trends in clinical research surrounding gamma delta cells, including their role in immunity and potential therapeutic applications
- Engage in a dynamic exchange of ideas and experiences, fostering collaboration among attendees to chart the future directions of gamma delta cell research in clinical practice

This session will include presentations from each speaker along with extensive discussion times, encouraging a whole room collaboration.



Jonathan Fisher
Principal Investigator
University College
London



Marta Barisa
Senior Manager - Scientific
Project & Research Fellow
University College London



Lawrence Lamb
Chief Scientific Officer &
Executive Vice President
IN8Bio



10.30 Morning Break & Refreshments

11:30 Roundtable Discussion: Promise, Perils and Progress when Publishing in Biotech

We have come through a major difficult period in funding for imaginative biotech, especially in the cell and gene therapy area. Although academics have been told to 'publish or perish', this is less clear in biotechnology.

- De-risking investment by having vetted science peer reviewed and published
- Formalizing reporting activities with suitable scientific controls allows the knowns and the unknowns to come to life
- Promoting a work culture that values the individual and groups and their contributions, realized in publication



Michael Lotze
Professor of Surgery, Immunology & Bioengineering
University of Pittsburgh

Delving into the Mechanisms and Pathways Underpinning Gamma Delta T Cell Cytotoxicity

12:15 Epigenetic Reprogramming of Immune Cells: Suplexa Offers Orthogonal and Complementary Technology to Gamma Delta Cells

- SUPLEXA technology is applicable to lymphoid immune cells, conferring upon them a number of anti-tumor functions
- First-generation autologous SUPLEXA cells tested in a first-in-human study demonstrates single-agent activity in multiple solid tumors
- The technology is compatible with a variety of engineering approaches mediated by viral and mRNA vectors



Frank Borriello
Founder & Chief Executive Officer
Alloplex Biotherapeutics

Bootcamp Day: Advancing Gamma Delta T Cell Therapies

Monday, July 29

5th Annual
**Gamma Delta T
Therapies Summit**
July 29-31, 2024 | **Boston, MA**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



1.00 Lunch & Networking

2:00 Immunotherapy, Surgery and $\gamma\delta$ T cells

- Pre-operative $\gamma\delta$ T cell functionality in the hostile microenvironment of solid tumours and responses to neoadjuvant immune checkpoint blockade immunotherapy
- Explore the distinct biology of $\gamma\delta$ T cells facilitating tissue residence, post-operative graft reconstitution and cancer immunosurveillance
- Developing novel strategies to reduce post-operative cancer recurrence targeting and employing $\gamma\delta$ T cells



Cathriona Foley
Assistant Professor
University College Cork

2:45 Round Table Discussion: Best Practices and Lessons Learned in Manufacturing Gamma Delta T Cells

- How to create a healthy relationship and the challenges associated with the CDMO during the early stages to streamline timelines
- Challenges when manufacturing processes are transferred from one facility to another facility
- Process tools and real time monitoring techniques to enhance understanding of the process and how to support continuous process improvements.



Jyothi Sethuraman
Director, MSAT
Adicet Bio

3.30 End of Biology Bootcamp Day

“The meeting was a great opportunity to learn from leaders in the field, both from academia and industry. Also a great forum to network. The organization was impeccable.”

Scientist, **Janssen**

Conference Day One

Tuesday, July 30



8.00 Registration & Coffee



Haiyan Jiang
Founder & Chief
Scientific Officer
**PointLoma
Biosciences**

8.30 Chair's Opening Remark

Clinical Advances in Liquid & Solid Tumors of Gamma Delta T Cell Therapies in 2024

9:00 **Panel Discussion: Reflecting on a Year of Industry Advances: Key Insights from 2023 & Anticipating the Path Ahead in 2024**

- Reviewing latest clinical updates and identifying key areas of opportunities in the past year
- Discussing the race to clinic and attracting investors to fund scale ups into the clinic
- Considering current gamma delta t therapies to drive solid tumor success
- What does 2024 look like for the field and where is it headed?



Lawrence Lamb
Chief Scientific Officer &
Executive Vice President
IN8Bio



Francesco Galimi
Chief Medical Officer
Adicet Bio



Sai-Wen Tang
Director - Research & Development
Acepodia



Stefanos Theoharis
Chief Executive Officer
OneChain Therapeutics



Bryan Kobel
Chief Executive Officer
TC Biopharma

9:45 **Clinical Data Update: DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells**



Trishna Goswami
Chief Medical Officer
IN8Bio

- DeltEx DRI Auto, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of newly diagnosed GBM solid tumors
- DeltEx Allo, is an allogeneic product candidate initially developed for the treatment of patients with acute leukemia
- DeltEx nsCAR-T INB-300 is our DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including the INB-330 program targeting CD-33 for AML



10:15 Morning Refreshments & Speed Networking

Research & Translational Development

Track Leader: Xiaohong Wang, R&D Director,
PointLoma Biosciences

Clinical Development & Product Optimization

Track Leader: Xiaohong Wang, Director, PointLoma
Biosciences

Fine-Tuning Mechanisms of Gamma Delta T Cells for Precise Solid Tumor Targeting

Streamlining Clinical Trial Design for Improved Targeting of the TME

11:15 Antibody-Cell Conjugation Technology: Cutting-Edge Platform for Off-the-Shelf Cell Therapies

- Advantages of ACC technology in developing allogeneic cell therapies
- Mechanism of action of antibody-conjugated gamma delta T cells against tumors
- Preclinical evidence of ACC products against hematologic and solid malignancies
- Updates for IND application of ACC products

Sai-Wen Tang, Director - Research & Development, **Acepodia**

11:15 Expanding the ImmTAX Platform to Gamma Delta T Cell Targets

- Introduction to the Immunocore ImmTAX platform and the first approved TCR bi-specific therapeutic.
- Establishment of a $\gamma\delta$ TCR discovery platform
- Development of an affinity enhanced $\gamma\delta$ TCR

Christopher Holland, Senior Manager, Research,
Immunocore Ltd

Conference Day One

Tuesday, July 30

11:45 Harnessing the Power of the Innate Immunity to Fight Solid Tumor

- Developing off-the-shelf allogeneic healthy donor-derived $\gamma\delta$ T cell therapy for solid tumor
- Polyclonal, natural composition of $\gamma\delta$ T cell subsets, leveraging the non-redundant functions of diverse subsets
- Armed and engineered dual CAR targets tumor and immune-suppressive stroma in the TME to optimize anti-tumor potency
- Gene editing to overcome immune suppression in the solid tumor TME

Haiyan Jiang, Founder & Chief Scientific Officer, **PointLoma Biosciences**

11:45 Leveraging the Best Practice When Designing and Running a CAR-T Clinical Trial in Autoimmune and Oncology Indications

- Operational and regulatory environment considerations surrounding CAR T trials in autoimmune and oncology - regulatory, patient care and site perspectives; current treatment landscape
- Practicalities of running a CAR T trial in U.S vs globally.
- Best approaches and strategies to build internal clinical operations team and CRO partnerships

Ekatherina Goryachikov, Head of Clinical Operations, **Adicet Bio**



12:15 Lunch & Networking

Exploration of Engineering Strategies & their Influence on Cellular Attributes

1:15 Ligand-Driven Activation Pathways of Gamma Delta T Cells

- What specific ligands can gamma delta TCR's target?
- Which of these ligands are involved in gamma delta T cell activation
- What new ligands are there that should be targeted?

Jonathan Fisher, Principal Investigator, **University College London**

Model Techniques in Developing $\gamma\delta$ T Cells at a Commercial Scale

1:15 Clinical Update: Gamma Delta Cell Therapy in Solid Tumors

- Safety and Efficacy of $\gamma\delta$ T cells treatment advanced cancer patients
- Minimally invasive treatment and immunotherapy for patients with advanced cancer
- Treatment and prevention of digestive system tumorous-related diseases Fecal Microbiota Transplant in cancer patients

Mohammed Alnaggar, Associate Professor, **Hubei University**

1:45 Establishment of an Allogeneic, Off-the-Shelf Platform for the Treatment of Solid Tumors

- Manufacturing of Deltacel, an allogeneic, non-engineered, off-the shelf Gamma Delta T -cell therapy
- Combination of Deltacel with low-dose irradiation to improve treatment outcomes
- Interim results from Phase I clinical trial
- Using Deltacel as a platform for the creation of targeted immunotherapies

Alan Guerrero, Vice President of Cell Therapy R&D, **Kiromic**

1:45 Clinical Update – TCB008 and the Journey to ACHIEVE

- An overview of TC BioPharm's clinical trial history that led to the development of our frozen off the shelf lead product
- Update of our current UK based clinical trial, ACHIEVE
- Outline of planned US based clinical trial and process development to enhance manufacturing capabilities and reducing costs

David Taggart, Product Development Supervisor, **TC Biopharm**

2:15 Novel Approach for Genome Editing of gdT Cells Using CRISPR And AAV

- The importance of site-directed CAR gene insertion vs random insertion mediated by lentivectors
- Studying the effect of cytokines on providing optimal gene editing conditions
- The importance of Homology directed repair activation and chromosomal accessibility for efficient CAR generation

Meisam Naemi Kararoudi, Assistant Professor, **Nationwide Children's Hospital**

2:15 Round Table: Dose-Escalation Protocols in Gamma Delta T Cell Therapies for Optimal Safety and Efficacy

- Determining the highest dose level that does not cause unacceptable toxicity or adverse effects
- Assessing the therapeutic efficacy of Gamma Delta T cell therapies at each dose level, aiming to find a balance between safety and clinical effectiveness
- Defining clear clinical endpoints and criteria for dose escalation

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. This is a dedicated opportunity for you to voice your experience and identify unique solutions.

Jose Ramon Conejo-Garcia, Chief Scientific Officer, **Cellepup**

Conference Day One

Tuesday, July 30



2:45 Afternoon Refreshments

Further Clinical Insights & Innovations in Gamma Delta T Therapeutics



Nelli Bejanyan
Program Lead
Moffitt Cancer Center

3:30 Clinical Unpublished Data: Allogeneic Gamma Delta Immunotherapy for Acute Myeloid Leukemia

- Novel findings on VD2s and VD1s remain unpublished currently
- Research aims to evaluate the efficacy, safety, and potential benefits of gamma delta cell therapy in treating AcuteAML
- Signifying the emergence of gamma delta cell therapy as a promising novel approach in AML management



Beau Webber
Chief Scientific Officer
Luminary Therapeutics

4:00 GDT & CAR-T Preclinical Dual Targeting & Engineering Gamma Delta Cells

- Novel set of CARs that address challenges head on for both hematological malignancy and solid tumors
- Our solid tumor program utilizes a Dual CAR architecture to target multiple cancer antigens and more completely eradicate cancerous cells with a single engineered T cell product
- Establish an allogeneic dual targeting CAR that will consist of CSPG4 and CD70



Haiyan Jiang
Founder & Chief
Scientific Officer
PointLoma Biosciences

4:30 Chairman's Closing Remarks

■ The speaker line-up was excellent and the panel discussions were informative ■

Account Executive, **Single Cell Discoveries**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Conference Day Two

Wednesday, July 31



8.00 Coffee & Networking



Haiyan Jiang
Founder & Chief
Scientific Officer
**PointLoma
Biosciences**

8.45 Chair's Opening Remarks

Clinical Advances in Liquid & Solid Tumors of Gamma Delta T Cell Therapies in 2024



Francesco Galimi
Chief Medical Officer
Adicet Bio

9:00 **Clinical Overview: Gamma Delta-Based Cell Therapy in Cancer & Autoimmune Diseases**

- Adicet pipeline of gamma-delta T cell therapies
- Clinical data in NHL
- Ongoing activities in gamma delta therapies for autoimmune disorders



Antara Banerjee
Senior Director, Head
Immune Cell Engager
Therapies
Takeda

9:30 **ADT3: A Potential First-In-Class EGFR X Vδ1 Bispecific Engager for In Situ Activation of Vδ1 γδ T Cells And Enhanced Cytotoxicity Towards Solid Tumors**

- ADT3 is a bispecific engager that is designed to activate tissue resident Vδ1 T cells
- ADT3 activates Vδ1 Gamma delta T cells via crosslinking through EGFR on tumor cells resulting in proliferation, activation and tumor cell killing
- Activation of Vδ1 cells via ADT3 enables activated Vδ1 cells to recognize and kill EGFR positive and EGFR negative tumor cells while sparing EGFR positive healthy cells



10.00 Morning Refreshments & Networking

Research & Translational Development

Track Leader: Payam Zarin, Associate Director,
GentiBio

Clinical Development & Product Optimization

Track Leader: Xiaohong Wang, Director, **PointLoma
Biosciences**

Contrasting Approaches in Gamma Delta T Cell Engagers and Cell Therapies

11:00 Gamma Delta – TIL As Guardians of Epithelia

- Epithelial tissues provide vital barrier and regulatory functions
- Gamma delta T cells stationed within epithelia act as frontline defenders, surveilling for threats and swiftly responding to maintain tissue integrity
- Their sentinel role involves continuous surveillance, rapid response to danger, and facilitation of tissue repair, crucial for overall host defense

Michael Lotze, Professor, UPMC Hillman Cancer Center

Enhancing Functionality of Gamma Delta T Cells Whilst Preserving Innate Killing Ability

11:00 Generation of highly active Vδ1 gamma delta T cells from stem cells, for the treatment of haematological and solid tumours

- Differentiation of Vδ1 gamma delta T cells using Notch ligands using cell-based and cell-free systems
- CD1a as a target for T-cell ALL using CAR- Vδ1T-cells
- Advantages versus autologous alphabeta CAR-T cells for T-cell malignancies

**Stefanos Theoharis, Chief Executive Officer, Onechain
Therapeutics**

11:30 Biology Guided Design of CAR GD T Cells for the Treatment of Solid Tumors

- Phenotypes of tumor-infiltrating gd T cells: What subsets we need to expand
- Expansion of clinically relevant amounts of gd T cells for treating human solid tumors
- Design of novel CAR architectures optimized for gd T cells
- CAR gd T cells control tumors expressing antigens absent from vital healthy tissues

Jose Ramon Conejo-Garcia, Chief Scientific Officer, Cellepux

11:30 Round Table: Indication Selection: GDT vs NK vs T Cells

- Consideration of indications where gamma delta T cells exhibit enhanced recognition of stress-induced antigens or phosphoantigens expressed by tumor cells as opposed to NK or alpha beta T cells
- Consideration of indications where gamma delta T cells can effectively target early or advanced-stage solid/liquid tumors over NK or alpha beta T cells
- Potential of introducing combinatory approaches with antibodies/checkpoint inhibitors or other immunomodulators to enhance efficacy

Roundtables are where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. This is a valuable chance for attendees to unite around hot topics and debate best practice. This is a dedicated opportunity for you to voice your experience and identify unique solutions.

**Laura Garcia Perez, Senior Scientist, OneChain
Immunotherapeutics**

Conference Day Two

Wednesday, July 31

12:00 The Role of gdT Cell Therapies in Autoimmunity

- An alternative to CD19 targeting
- Identifying and removing autoreactive B cells by directly targeting the B cell activating factor receptors
- Eliminating the cause of inflammation at the source

Jeff Liter, Chief Executive Officer, **Luminary Therapeutics**

12:00 Clinical Case Study: Lessons Learned in Phase 1

- A step-by-step guide on preparing and submitting an IND application: Regulatory requirements for IND submission and best practices for engaging with regulatory agencies during the IND filing process
- Sharing lessons learned from being in the clinic, addressing unexpected regulatory challenges in the clinic and incorporating lessons learned into future development strategies

Nelli Bejanyan, Associate Professor, **Moffitt Cancer Center**



12.30 Lunch & Networking

The Role of Gamma Delta T Cells in Autoimmune Diseases

1:30 Clinical Data: Bridging Allogeneic CAR-Gamma Delta T Cell to The Clinic

- Tailoring manufacturing platform to expand high-quality engineered gamma delta T products
- Demonstrating preclinical activity of CAR-gamma delta T cells for solid tumors and autoimmune diseases
- Sharing the clinical data of B7H3 CAR-gamma delta T cell therapy for r/r GBM treatment

Weiwei Ma, Chief Technology Officer, **Unicet Biotech**

Regulatory Focus on Allogeneic Off-the-Shelf Gamma Delta T Cell Therapies

1:30 Regulatory Overview on Past & Present Gamma Delta T Cell Therapies

- An overview on the current regulatory landscape for allogeneic therapies and discussing any anticipated changes and trends in the regulatory environment for future allogeneic therapies
- Exploration of potential challenges and opportunities in the evolving regulatory landscape and discussing how to use adaptive strategies to address regulatory uncertainties

Lawrence Lamb, Chief Scientific Officer & Executive Vice President, **IN8Bio**

2:00 Fireside Chat: Next Generation GDT Cell Therapy for Autoimmune Disorders

- Exploration of preclinical and clinical evidence supporting the use of gamma delta cell therapies in autoimmune conditions.
- Addressing safety considerations and potential adverse effects associated with gamma delta cell treatments.
- Evaluation of the challenges and opportunities in translating gamma delta cell therapies from bench to bedside for autoimmune diseases.
- Consideration of patient selection criteria and personalized treatment approaches.
- Insights into ongoing research and future directions in the field of gamma delta cell therapy for autoimmune disorders

Jeff Liter, Chief Executive Officer, **Luminary Therapeutics**
Francesco Galimi, Chief Medical Officer, **Adicet Bio**
Ed Zhang, CEO, **Overland Pharmaceuticals**

2:00 Audience Led Discussion: Pushing Pipeline into the Clinic

- Establishing a comprehensive understanding of the regulatory landscape for allogeneic off-the-shelf gamma delta T cell therapies
- Covering key aspects such as regulatory considerations for the future, prepping for a BLA, IND filing procedures and overall navigating the journey from IND filing to getting into the clinic
- Open mic for direct questions with industry KOLs

Lawrence Lamb, Chief Scientific Officer & Executive Vice President, **IN8Bio**

Nelli Bejanyan, Associate Professor, **Moffitt Cancer Center**

Conference Day Two

Wednesday, July 31



2.30 Afternoon Refreshments & Networking

Taking Proactive & Strategic Next Steps in Gamma Delta T Therapy Development



Charlie Morris
Chief Medical Officer
LAVA Therapeutics

3:00 Clinical Potential: GAMMABODY Platform

- Generating bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called V γ 9V δ 2 (Vgamma9 Vdelta2) T cells
- Complementing natural tumor recognition, direct V γ 9V δ 2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade
- Demonstrating superior efficacy and safety profiles compared to other bispecific T cell engagers approaches



Nandhu Sobhana
Head of Cell Therapy
Innovation IND Engine
Takeda

3:30 The Development of V δ 1 Gamma Delta T cell Platforms For Use In Next-Generation Allogeneic CAR Therapies

- Harnessing the potential of $\gamma\delta$ T cells for immunotherapy in solid and hematological malignancies
- Investigating the advancements of allogeneic V δ 1 $\gamma\delta$ T cell therapy platforms
- Preclinical update on the progress of cell therapy programs utilizing V δ 1 $\gamma\delta$ T cells



Haiyan Jiang
Founder & Chief
Scientific Officer
**PointLoma
Biosciences**


4:00 Chair's Closing Remarks

4:15 Close of Summit

“ There was an excellent mix of academia and drug developer folks, so this is a great venue of learning gdT cell biology and the progress of developing gdT cell therapies. ”

Associate Principal Scientist, **Merck & Co**

Our Partners



5th Annual
**Gamma Delta T
Therapies Summit**

July 29-31, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



IMU – Innovation Partner

IMU was founded on the belief that deep immunophenotyping at population level scale powered by machine learning could unlock the power of the immune system to help develop the next generation of immune medicines. We believe that in the future, no medical decision will be made without an understanding of a patient's immune system.

www.imubiosciences.com



Ingenious targeting laboratory – Innovation Partner

Established in 1998, ingenious targeting laboratory (ingenious) is a leading global provider of custom genetically modified mouse, rat, and rabbit models. Our trusted gene editing service is built on over two decades' worth of successful animal model creation for investigators, organizations, and companies in 44 states and 28 countries. We establish and maintain strong client relationships and support, and ensure the highest quality of our products. Our clients retain full intellectual property rights to their projects and benefit from full confidentiality.

www.genetargeting.com



ScaleReady – Exhibition Partner

ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.

www.scaleready.com



iRepertoire Inc – Exhibition Partner

iRepertoire's patented and proprietary amplification technologies set the gold standard for reliable and reproducible sequencing of T-cell and B-cell receptor chain (VDJ) regions from a variety of clinical sample types. These core technologies enable both pairwise cognate chain sequencing from FACS isolated single cells and also comprehensive 7-chain bulk repertoire analysis with quantitative transcript-level barcoding (UMI). Recent studies demonstrate the utility of iRepertoire's sequencing technologies for evaluating treatment efficacy in pre-clinical studies and identifying antigen-specific T-cells in response to novel therapies.


www.irepertoire.com

GET INVOLVED



Luke O'Neill
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us



5th Annual
Gamma Delta T
Therapies Summit

July 29-31, 2024 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Exclusive Platform To Build Relationships Within The Rapidly Growing Gamma-delta T Cell Therapies Field

Showcase yourself as a dedicated solution provider to an engaged audience to educate senior industry leaders on how you could help streamline and accelerate therapy development.



Meet Senior Decision Makers:

Our meeting will unite everyone from CEOs, CSOs, VPs, directors to technical leaders involved in early R&D through to the clinic, creating a niche environment so you can network directly with the most senior decision makers in the industry



Educate the Industry:

Secure a speaking position to explain how your solutions can directly support potential clients who are actively seeking new solutions to optimize drug development inefficiencies




Align your Brand with the Only Gamma Delta T Focused Forum:

Stand out as a key thought leader through exclusive presentations, structured and informal networking sessions

Connect and build valuable relationships with key stakeholders to ensure you meet your 2024 commercial and strategic goals!

SENIORITY OF ATTENDEES*



Chief / CxO: 13%

Director: 17%

Head: 5%

President / VP: 6%


Professor: 4%

Project / Team: 10%

Scientist: 25%

Other: 20%

TYPES OF COMPANIES ATTENDING*



*Based on 2023 statistics

GET INVOLVED



Luke O'Neill
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



<https://gamma-delta-t-therapies.com/take-part/register/>



Tel: +1 617 455 4188



Email: info@hansonwade.com



ENGAGE with industry leaders as they discuss novel insights on maximizing therapeutic impact of gamma delta T cells



DE-RISK your pathway to market with key insights on novel techniques to identify the windows of opportunity for the future of gamma delta T therapeutics



DISCOVER novel clinical case studies from leading pharma and biotech companies to take away their key challenges and how your company can deliver the best solutions to their teams

Industry Pricing*	Register & Pay by Friday, May 10	On the Door Price
Conference + Bootcamp Day	\$3,347	\$4,197
Conference Only	\$2,449	\$2,999

Solution Provider Pricing	Register & Pay by Friday, May 10	On the Door Price
Conference + Bootcamp Day	\$4,247	\$5,097
Conference Only	\$3,149	\$3,699

Academic Pricing**	Register & Pay by Friday, May 10	On the Door Price
Conference + Bootcamp Day	\$2,747	\$3,597
Conference Only	\$2,049	\$2,599

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5 + Attendees

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hilton Boston Back Bay

40 Dalton St Boston, Massachusetts, 02115, USA

<https://www.hilton.com/en/hotels/bosbhhl-hilton-boston-back-bay/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

